Tilray (NASDAQ:TLRY) Shares Down 1.4% - Should You Sell?

Tilray Inc (NASDAQ:TLRY - Get Free Report)'s share price was down 1.4% during trading on Tuesday . The stock traded as low as $1.08 and last traded at $1.09. Approximately 12,897,415 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 41,539,746 shares. The stock had previously closed at $1.10.

Wall Street Analyst Weigh In

TLRY has been the topic of several research analyst reports. Roth Mkm reduced their price objective on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a report on Friday, October 11th. Canaccord Genuity Group increased their price objective on shares of Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $2.70.

Tilray Stock Performance

The stock has a market capitalization of $989.23 million, a PE ratio of -3.52 and a beta of 2.08. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. The firm's 50 day moving average is $1.28 and its two-hundred day moving average is $1.56.

Tilray (NASDAQ:TLRY - Get Free Report) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.07). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $210.90 million during the quarter, compared to analyst estimates of $216.34 million. The firm's quarterly revenue was up 8.7% on a year-over-year basis. As a group, research analysts predict that Tilray Inc will post -0.2 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Carl A. Merton acquired 26,000 shares of the company's stock in a transaction on Friday, November 15th. The shares were bought at an average price of $1.36 per share, with a total value of $35,360.00. Following the completion of the acquisition, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.87% of the company's stock.

Institutional Trading of Tilray

A number of large investors have recently bought and sold shares of TLRY. Ferguson Wellman Capital Management Inc. acquired a new stake in shares of Tilray during the third quarter worth about $26,000. Ameritas Advisory Services LLC acquired a new stake in Tilray during the 4th quarter worth approximately $32,000. Newman Dignan & Sheerar Inc. increased its holdings in shares of Tilray by 61.9% in the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock valued at $35,000 after purchasing an additional 10,000 shares during the period. International Assets Investment Management LLC raised its stake in shares of Tilray by 335.3% during the third quarter. International Assets Investment Management LLC now owns 23,639 shares of the company's stock worth $42,000 after purchasing an additional 18,208 shares during the last quarter. Finally, Vista Capital Partners Inc. purchased a new stake in shares of Tilray during the third quarter worth approximately $42,000. Institutional investors and hedge funds own 9.35% of the company's stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.